Idera Presents Preclinical Data at ASCO on Agonists to Toll-like Receptor 9 in Combination with Chemotherapeutic and Targeted T
June 05 2006 - 8:01AM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) today announced that it had
presented preclinical data for its TLR9 agonists in mouse lung
cancer models at the American Society of Clinical Oncology (ASCO)
Annual Meeting. These data demonstrate that in the preclinical
studies conducted by Idera, Idera's TLR9 agonists enhanced the
antitumor effect of several common chemotherapeutic agents
including Gemzar(R) and Alimta(R) and the targeted cancer therapy
Tarceva(R), and also had monotherapy activity. The new observations
with Tarceva add to previous preclinical data developed by Idera
collaborators of synergistic activity between Idera's TLR9 agonists
and other EGFR inhibitors. Idera's lead TLR9 agonist IMO-2055 is
currently in Phase 2 and Phase 1/2 clinical trials for renal cell
carcinoma and for non-small cell lung cancer, respectively. "These
preclinical data reinforce the broad-spectrum potential of Idera's
Toll-like Receptor targeted drugs and further substantiate our
clinical oncology programs for IMO-2055," commented Robert W. Karr,
M.D., President of Idera. "In addition to our oncology clinical
trials with IMO-2055, we have a Hepatitis C preclinical development
program underway with a second TLR9 agonist and a collaboration
with Novartis to evaluate other TLR9 agonists in asthma/allergy."
"We believe that the broad applicability of our TLR9 agonist
programs as well as our recently announced portfolio of TLR7/TLR8
agonists and TLR9 antagonists for potential applications in various
diseases gives Idera one of the most comprehensive TLR portfolios
in the industry," continued Dr. Karr. The presentation of abstract
number 2568 titled, "Antitumor activity of a synthetic agonist of
TLR9 in preclinical lung cancer models" was given in a poster at
the ASCO session Developmental Therapeutics: Immunotherapy on
Sunday June 4th, 2006. The presentation included data from murine
non-small cell lung cancer models in combination with Gemzar,
cyclophosphamide, Alimta and Tarceva. In the preclinical studies,
combination with Idera's TLR9 agonists increased the antitumor
activity of each of the agents. About IMO-2055 IMO-2055 is Idera's
lead Toll-like Receptor 9 (TLR9) agonist for the treatment of
cancer and is based on Idera's proprietary Immune Modulatory
Oligonucleotide (IMO(TM)) technology. IMO-2055 is currently in
Phase 2 trials in renal cell carcinoma and Phase 1 trials in
non-small cell carcinoma. The Company has previously conducted a
Phase 1 monotherapy trial of IMO-2055 in solid tumor oncology
patients at Georgetown University Medical Center, data from which
was reported at ASCO 2005. About Idera Pharmaceuticals, Inc. Idera
Pharmaceuticals, Inc. (AMEX: IDP) is a Cambridge, Massachusetts
biotechnology company focused on the discovery and development of
targeted immune therapies based on modulation of Toll-like
Receptors (TLRs). Drug candidates targeting TLRs have broad
commercial potential in the areas of oncology, infectious disease,
and allergy/asthma. Idera's most advanced clinical candidate,
IMO-2055, is an agonist of TLR9 and is currently in a Phase 2
monotherapy trial in renal cell carcinoma, and in a Phase 1/2
chemotherapy combination therapy trial in solid tumors. Idera has
selected another TLR9 agonist, IMO-2125, as a lead candidate for
infectious diseases. Idera also is collaborating with Novartis for
the discovery, optimization, development, and commercialization of
additional TLR9 agonist candidates for asthma and allergy. For more
information, visit www.iderapharma.com. Forward Looking Statements
This press release contains forward-looking statements concerning
Idera Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated by such
forward-looking statements, including whether the preclinical data
referenced in this release will be indicative of results from
clinical studies of IMO-2055; whether products based on Idera's
technology such as IMO-2055 will advance into or through the
clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials in the time expected;
whether, if the Company's products such as IMO-2055 receive
approval, they will be successfully distributed and marketed;
whether the results of preclinical studies will be indicative of
results that may be obtained in clinical trials; whether Idera's
cash resources will be sufficient to fund product development and
clinical trials; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on
Form 10-Q filed on May 12, 2006, which important factors are
incorporated herein by reference. Idera disclaims any intention or
obligation to update any forward-looking statements. Gemzar(R) and
Alimta(R) are registered trademarks of Eli Lilly and Company.
Tarceva(R) is a registered trademark of Genentech, Inc.
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceutical (AMEX:IDP)
Historical Stock Chart
From Jul 2023 to Jul 2024